

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
☐	☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒ The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
☒	☐ A description of all covariates tested
☒	☐ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐	☒ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
☒	☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☒	☐ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	Laser scanning confocal microscope (Leica TCS SP8, Germany), flow cytometry (BD Accuri C6), multi-plate reader (Infinite 200 PRO, Switzerland), scanning electron microscopy (S4800), electromechanical universal testing machine (CMT6502), Computed Tomography (Nano Voxel 1-2702E).
Data analysis	General data were analyzed by graphpad prism 8.0.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All the main data supporting the results are available within the main text and supplementary information. Source data are provided in source data file.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender N/A

Reporting on race, ethnicity, or other socially relevant groupings N/A

Population characteristics N/A

Recruitment N/A

Ethics oversight N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size Sample size were provided in the figure caption for each experiment and reasonable sample sizes were chosen to ensure they are sufficient for statistical comparison between different groups.

Data exclusions No samples were excluded.

Replication Experiment were repeated and experimental findings were reproducible. Details of experimental replicates were given in the figure legends.

Randomization All samples were randomly allocated into experimental groups.

Blinding Except for device construction, all other experiments were blinded to group allocation during data collection and analysis.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☐	☒ Antibodies
☐	☒ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☐	☒ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☐	☒ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used Anti-syntenin-1 (ab315342 1:1000), Anti-Alix (ab275377 1:1000), Anti-TSG101 (ab125011 1:1000), Anti-CD63 (ab217345 1:1000), Anti-CD9 (ab307085 1:1000), Anti-CD68 (ab303565 1:1000) were purchased from Abcam. Anti-GRP94 was purchased from CST.

Validation

[https://www.abcam.com/;](https://www.abcam.com/)
[https://www.cellsignal.com/;](https://www.cellsignal.com/)

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

Cell lines used in the experiments were purchased from ATCC.

Authentication

Identification of the cell lines were checked by morphology and growth characteristics according to the manufacturer's instructions and were used without any modification.

Mycoplasma contamination

All cell lines were tested negative for mycoplasma contamination. No mycoplasma contamination was found.

Commonly misidentified lines
(See [ICLAC](#) register)

No commonly misidentified cell lines were used.

Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals

10-week-old female Sprague Dawley rats

Wild animals

No wild animals were used.

Reporting on sex

Female rats were used for the in vivo study.

Field-collected samples

No field-collected samples were used.

Ethics oversight

All Animal experiments were carried out in accordance with ethical guidelines and approved by the Committee for Animal Research of Nanjing University of Posts and Telecommunications

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plants

Seed stocks

N/A

Novel plant genotypes

N/A

Authentication

N/A

Flow Cytometry

Plots

Confirm that:

- ☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☒ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Differential centrifugation was used to isolate and concentrate EVs. First, all the culture supernatant was collected and centrifuged at 3,000g for 20 minutes to remove cell debris and larger particles. Then the cleared supernatant was subjected to 10,000g for 30 minutes at 4°C. After that, the obtained solution was subjected to ultracentrifugation at 100,000g for 2 hours at 4°C.

Instrument	Flow cytometry (BD Accuri C6)
Software	FlowJo v10.8.1
Cell population abundance	10 ⁹ -10 ¹⁰ cells/mL
Gating strategy	Cell were gated based on size and granularity of forward and side scatter and further analyzed for specific fluorescence.

☒ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.